Cargando…
FXYD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness: Its Relationship With TGF-β1 and NF-κB Pathways
Objective: Endometrial cancer (EC) is the second most common gynecological cancer worldwide. Myometrial invasion (MI) is a key event in EC dissemination. This study aimed to evaluate FXYD5/dysadherin (FXYD5/Dys) expression in EC tissue and uterine aspirate (UA) biopsies and to assess molecular/funct...
Autores principales: | Besso, María José, Rosso, Marina, Lapyckyj, Lara, Moiola, Cristian Pablo, Matos, María Laura, Mercogliano, María Florencia, Schillaci, Roxana, Reventos, Jaume, Colas, Eva, Gil-Moreno, Antonio, Wernicke, Alejandra, Orti, Roberto, Vazquez-Levin, Mónica Hebe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6908519/ https://www.ncbi.nlm.nih.gov/pubmed/31867269 http://dx.doi.org/10.3389/fonc.2019.01306 |
Ejemplares similares
-
Characterization of the molecular changes associated with the overexpression of a novel epithelial cadherin splice variant mRNA in a breast cancer model using proteomics and bioinformatics approaches: identification of changes in cell metabolism and an increased expression of lactate dehydrogenase B
por: Rosso, Marina, et al.
Publicado: (2019) -
E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness
por: Rosso, Marina, et al.
Publicado: (2017) -
FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients
por: Tassi, Renata A., et al.
Publicado: (2019) -
Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes
por: Jang, Samuel, et al.
Publicado: (2017) -
Ephrin-B1 Is a Novel Biomarker of Bladder Cancer Aggressiveness. Studies in Murine Models and in Human Samples
por: Mencucci, María Victoria, et al.
Publicado: (2020)